
| Disease Domain | Count |
|---|---|
| Neoplasms | 7 |
| Nervous System Diseases | 5 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 10 |
| Top 5 Target | Count |
|---|---|
| ACHE x BCHE | 8 |
| Cholinesterase | 2 |
Target |
Mechanism Cholinesterase inhibitors |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism AChE inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism AChE inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Jan 2027 |
Sponsor / Collaborator |
Start Date15 Oct 2026 |
Sponsor / Collaborator |
Start Date01 Aug 2026 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Compound 5h(Kahramanmaraş Sütçü İmam University) ( ACHE x BCHE ) | Alzheimer Disease More | Preclinical |
Compound 5c(Kahramanmaraş Sütçü İmam University) ( ACHE x BCHE ) | Alzheimer Disease More | Preclinical |
Compound 6d(Kahramanmaras Sutcu Imam University) ( Cholinesterase ) | Neurodegenerative Diseases More | Preclinical |
Compound 5e(Kahramanmaraş Sütçü İmam University) ( ACHE x BCHE ) | Alzheimer Disease More | Preclinical |
Compound 5a(Kahramanmaras Sutcu Imam University) ( Cholinesterase ) | Neurodegenerative Diseases More | Preclinical |





